Holm Thomas Lindebo, Tornehave Ditte, Søndergaard Henrik, Kvist Peter Helding, Sondergaard Bodil-Cecilie, Hansen Lene, Hermit Mette Brunsgaard, Holgersen Kristine, Vergo Sandra, Frederiksen Klaus Stensgaard, Haase Claus, Lundsgaard Dorthe
Global Research, Novo Nordisk A/S, Maaloev, Denmark.
Novo Nordisk LIFE In Vivo Pharmacology Centre, Frederiksberg, Denmark.
Gastroenterol Res Pract. 2018 Apr 10;2018:5962624. doi: 10.1155/2018/5962624. eCollection 2018.
Interleukin-21 (IL-21) is primarily a T cell-derived cytokine; it is upregulated in patients with Crohn's Disease (CD) and could be a potential new therapeutic target in CD.
In human material, IL-21 and IL-21R expression was investigated by in situ hybridization (ISH) and immunohistochemistry (IHC) in noninflammatory bowel disease (non-IBD) controls and patients with CD. The pathologic role of IL-21 was examined in murine models of T cell-dependent and T cell-independent colitis, either with a neutralizing monoclonal antibody against IL-21 or with the transfer of CD4CD45RBIL-21R T cells. Colonic pathology was examined by endoscopy, histopathology, IHC, ELISA, and Luminex.
In the human intestine, IL-21 and IL-21R mRNA and protein-expressing cells were observed in the mucosa, in lymphoid aggregates of submucosa in non-IBD controls, and in lymphoid aggregates of muscularis externa in patients with CD. IL-21 expression was most abundant in germinal centers (GCs) of the lymphoid aggregates, and IL-21R expression assessed semiquantitatively, was significantly higher in patients with CD compared to non-IBD controls. Following prophylactic and interventive anti-IL-21 mAb treatment in the adoptive transfer (AdTr) model, clinical and pathological parameters were significantly reduced. The most persistent finding was a reduction in colonic infiltrating neutrophils. As well, Rag2 mice receiving CD4CD45RBIL-21R T cells developed less severe colitis compared to Rag2 mice receiving CD4CD45RBIL-21R T cells. No effect of reduced IL-21 signalling was observed in T cell-independent colitis.
Our study shows that patients with CD have significant expression of IL-21 and IL-21R in the gut. As well, we show that neutralization of IL-21 in experimental T cell-driven colitis is associated with a reduction in clinical and pathological findings. This amelioration seems to be associated with a reduction in colon-infiltrating neutrophils.
白细胞介素-21(IL-21)主要是一种由T细胞衍生的细胞因子;它在克罗恩病(CD)患者中上调,可能是CD潜在的新治疗靶点。
在人体材料中,通过原位杂交(ISH)和免疫组织化学(IHC)研究非炎症性肠病(非IBD)对照和CD患者中IL-21和IL-21R的表达。使用抗IL-21的中和单克隆抗体或通过转移CD4CD45RBIL-21R T细胞,在T细胞依赖性和T细胞非依赖性结肠炎的小鼠模型中研究IL-21的病理作用。通过内窥镜检查、组织病理学、IHC、ELISA和Luminex检测结肠病理学。
在人类肠道中,在非IBD对照的黏膜、黏膜下层淋巴聚集处以及CD患者的肌层淋巴聚集处观察到IL-21和IL-21R mRNA及蛋白表达细胞。IL-21表达在淋巴聚集处的生发中心最为丰富,与非IBD对照相比,CD患者中半定量评估的IL-21R表达显著更高。在过继转移(AdTr)模型中进行预防性和干预性抗IL-21单克隆抗体治疗后,临床和病理参数显著降低。最持续的发现是结肠浸润中性粒细胞减少。同样,与接受CD4CD45RBIL-21R T细胞的Rag2小鼠相比,接受CD4CD45RBIL-21R T细胞的Rag2小鼠发生的结肠炎较轻。在T细胞非依赖性结肠炎中未观察到IL-21信号传导降低的影响。
我们的研究表明,CD患者肠道中IL-21和IL-21R有显著表达。此外,我们表明在实验性T细胞驱动的结肠炎中中和IL-21与临床和病理结果的降低有关。这种改善似乎与结肠浸润中性粒细胞的减少有关。